Study guide
11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
Key Takeaways Explain This Topic AI
Trial of Labor After Cesarean (TOLAC) is an evidence-based option for individuals with one or two prior low transverse cesarean deliveries and a clinically adequate pelvis; successful VBAC achieves a 60%–80% success rate and significantly lower maternal morbidity than elective repeat cesarean delivery (ERCD).
Absolute contraindications to TOLAC include prior classical (vertical fundal) or inverted-T uterine incisions, prior documented uterine rupture, extensive transfundal uterine surgery entering the endometrial cavity, or labor in a facility without immediate capability for emergency laparotomy/cesarean delivery.
While cautious oxytocin augmentation is permissible during TOLAC, prostaglandin ripening agents should be avoided (ACOG specifically states misoprostol should not be used) because they raise the risk of uterine rupture.
The cardinal and most sensitive clinical harbinger of uterine rupture is sudden, acute fetal heart rate abnormalities (prolonged fetal bradycardia or recurrent late/variable decelerations, occurring in >70% of cases), accompanied by severe abdominal pain, loss of fetal station, cessation of uterine contractions, and maternal hypovolemia.
Life-threatening intrapartum emergencies require rapid execution of standardized protocols: umbilical cord prolapse requires immediate manual elevation of the presenting part, maternal knee-chest positioning, and emergency cesarean; shoulder dystocia requires execution of the HELPERR algorithm with avoidance of fundal pressure; and amniotic fluid embolism presents with sudden catastrophic hypoxia, cardiogenic collapse, and consumptive coagulopathy (DIC).
Last updated: October 2026
Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
Intrapartum care requires evidence-based shared decision-making for patients seeking Vaginal Birth After Cesarean (VBAC) combined with immediate readiness to manage life-threatening obstetric emergencies: uterine rupture, umbilical cord prolapse, shoulder dystocia, and amniotic fluid embolism (AFE).
Trial of Labor After Cesarean (TOLAC) & VBAC
A Trial of Labor After Cesarean (TOLAC) is a planned labor attempt in a patient with a prior cesarean, aiming to achieve a Vaginal Birth After Cesarean (VBAC).
Candidate Selection & Contraindications
According to ACOG guidelines:
Eligible Candidates: One or two prior low transverse cesarean deliveries (low transverse incisions involve the non-contractile lower uterine segment, carrying the lowest rupture risk: 0.5%–0.9% for one, 1.0%–1.5% for two); clinically adequate maternal pelvis; singleton cephalic pregnancy; and immediately available emergency surgical and anesthesia teams.
VBAC Success: Success rates range from 60% to 80% . Prior vaginal delivery, especially a prior VBAC, is the single strongest clinical predictor of success.
Absolute Contraindications to TOLAC:
Prior classical (vertical fundal) or inverted-T / J-shaped incision (carries a 4% to 9% rupture risk).
Prior documented uterine rupture (subsequent rupture risk is 18% to 32%).
Prior extensive transfundal uterine surgery entering the endometrial cavity (e.g., transmural myomectomy).
Standard obstetric contraindications to vaginal birth (e.g., placenta previa).
Inability to perform immediate emergency cesarean delivery.
Induction & Augmentation Rules in TOLAC
Mechanical cervical ripening with a transcervical Foley balloon catheter is safe and effective.
Oxytocin may be used cautiously for induction or augmentation.
Prostaglandins: ACOG Practice Bulletin 205 states that misoprostol should not be used for third-trimester ripening or induction after a prior cesarean or major uterine surgery; prostaglandins in general are avoided for TOLAC, and mechanical ripening is preferred.
Caution
Avoid prostaglandin ripening agents (especially misoprostol) in a patient with a prior cesarean scar who is attempting TOLAC; use a Foley balloon and cautious oxytocin instead.
Uterine Rupture: Clinical Signs & Management
Uterine rupture involves complete disruption of all myometrial layers, visceral peritoneum, and amniotic membranes:
Cardinal Feature: Sudden, prolonged fetal heart rate decelerations or terminal bradycardia (<110 bpm) , present in 70% to 80% of ruptures .
Other Classic Signs: Sudden severe, tearing breakthrough abdominal pain (persisting despite active epidural); sudden cessation of uterine contractions; loss of fetal station (presenting part retreats out of the pelvis); maternal hypovolemic shock; and vaginal bleeding or hematuria.
Management: Immediate emergent laparotomy with general anesthesia, rapid fetal delivery, neonatal resuscitation, aggressive crystalloid and blood product replacement, and surgical repair or emergency hysterectomy.
Umbilical Cord Prolapse
Umbilical cord prolapse occurs when the cord slips alongside or below the fetal presenting part, causing acute compression between the fetus and maternal bony pelvis.
Etiology & Presentation
Risk Factors: Unengaged presenting part (-3 station or higher), malpresentation (transverse lie, footling breech), polyhydramnios, prematurity, or iatrogenic rupture of membranes ( amniotomy at high station ).
Clinical Findings: Sudden, severe, prolonged fetal bradycardia or profound variable decelerations immediately following membrane rupture, with a visible or palpable pulsating cord loop in the vagina.
Emergency Management Protocol
Call for Help: Immediately mobilize obstetric, anesthesia, surgical, and neonatal teams.
Manual Elevation of Presenting Part: Insert a sterile gloved hand into the vagina and push the fetal head upward off the cord. Maintain continuous upward elevation until abdominal delivery!
Maternal Postural Decompression: Place mother in knee-chest position or steep Trendelenburg to enlist gravity in lifting the fetus off the cord.
Retrograde Bladder Filling: Instill 500 mL sterile normal saline via Foley catheter and clamp tubing; the filled bladder maintains cephalad displacement of the fetus during transfer.
Administer Tocolysis: Give terbutaline 0.25 mg subcutaneously to halt uterine contractions.
Protect Protruding Cord: Cover exposed cord loosely with warm, saline-soaked sterile gauze; avoid digital manipulation to prevent vasospasm. Never attempt to replace the cord.
Immediate Emergency Cesarean Delivery: Proceed directly to emergent operative delivery.
Shoulder Dystocia & The HELPERR Protocol
Shoulder dystocia occurs when the anterior fetal shoulder impacts against the maternal pubic symphysis (or posterior shoulder against the sacral promontory) following delivery of the head.
Recognition & Risk Factors
Risk Factors: Fetal macrosomia (>4,500 g, or >4,000 g in diabetic gravidas), maternal diabetes, prior shoulder dystocia, excessive gestational weight gain, and operative vaginal delivery. Over 50% occur in normal-weight infants without risk factors.
Turtle Sign: The fetal head retracts tightly against the perineum following expulsion; gentle downward traction fails to deliver the anterior shoulder.
The HELPERR Mnemonic Protocol
Step Action Execution Details & Clinical Mechanics
H Call for Help Mobilize obstetrician, neonatologist, anesthesia, and extra nurses; designate a timekeeper (<4–5 min window to prevent hypoxic brain injury).
E Evaluate for Episiotomy Shoulder dystocia is a bony impaction; episiotomy does not release the shoulder but facilitates space for internal maneuvers.
L Legs: McRoberts Maneuver First-line maneuver. Hyperflex maternal thighs sharply against abdomen. Flattens sacral promontory and rotates symphysis pubis cephalad, resolving 40%–50% of cases.
P Suprapubic Pressure Apply downward and lateral pressure over maternal suprapubic region to adduct and disimpact the anterior shoulder under the pubic ramus.
E Enter Internal Maneuvers 1. Rubin II: Push posterior aspect of anterior shoulder toward fetal chest (adduction). (2) Woods Screw: Rotate posterior shoulder 180 degrees in screw-like motion. (3) Reverse Woods Screw: Rotate in opposite direction.
R Remove Posterior Arm Sweep posterior arm across chest and deliver hand/arm, reducing bisacromial diameter by 2–3 cm.
R Roll onto All Fours (Gaskin) Transition to hands and knees; alters pelvic geometry to facilitate delivery.
Caution
STRICTLY PROHIBITED: Never apply uterine fundal pressure! Fundal pressure further impacts the shoulder, dramatically increasing rates of permanent brachial plexus injury (Erb palsy), clavicle fracture, and fetal death.
Salvage Maneuvers: Deliberate clavicular fracture, Zavanelli maneuver (cephalic replacement followed by emergency cesarean), symphysiotomy.
Complications: Neonatal brachial plexus injury (Erb palsy C5–C6, Klumpke palsy C8–T1), clavicle/humerus fracture, hypoxic-ischemic encephalopathy (HIE); maternal postpartum hemorrhage, 3rd/4th-degree lacerations.
Amniotic Fluid Embolism (AFE)
AFE (Anaphylactoid Syndrome of Pregnancy) is an unpredictable, catastrophic obstetric emergency triggered by the entry of amniotic fluid and fetal debris into maternal venous circulation, initiating massive complement activation and anaphylactoid shock.
Classic Clinical Triad
Sudden Acute Hypoxia / Respiratory Failure: Abrupt dyspnea, cyanosis, and profound desaturation (SpO2 <80%).
Cardiogenic Shock / Hemodynamic Collapse: Acute right heart failure, severe pulmonary hypertension, left ventricular collapse, hypotension, and cardiac arrest.
Consumptive Coagulopathy / DIC: Profound hypofibrinogenemia (<150 mg/dL), acute hemorrhage from venipuncture/surgical sites, and thrombocytopenia.
Emergency Resuscitation Protocol
ACLS & Left Uterine Displacement (LUD): High-quality chest compressions with continuous left lateral uterine displacement.
Resuscitative Hysterotomy (Perimortem Cesarean): If cardiac arrest occurs and spontaneous circulation is not restored within 4 minutes , deliver the fetus at bedside by minute 5 . Uterine evacuation relieves vena caval compression, increasing maternal CPR effectiveness by 60%.
Intubation & Inotropes: Immediate intubation with 100% FiO2; administer norepinephrine, epinephrine, or milrinone.
Massive Transfusion Protocol (MTP): Transfuse RBCs, FFP, and platelets in a balanced 1:1:1 ratio ; give cryoprecipitate to keep fibrinogen above 150–200 mg/dL, and IV tranexamic acid (TXA) 1 g within 3 hours of bleeding onset.